SYNAPS Dx Releases Autopsy-Confirmed Results for DISCERN™ Alzheimer’s Test and Physicians’ Assessment of Clinical Utility of DISCERN at BRAINWeek 2023
AD fibroblast cells form larger aggregates in contrast to non-AD dementia (non-ADD) or non-dementia control (NDC) samples, which formed smaller and more numerous aggregates.
- AD fibroblast cells form larger aggregates in contrast to non-AD dementia (non-ADD) or non-dementia control (NDC) samples, which formed smaller and more numerous aggregates.
- These findings were collected using a double-blind protocol for demented patients over the age of 55 and eventually confirmed through an autopsy study.
- The clinical utility study from a sample of 402 primary care physicians (PCPs) including 250 PCPs, 102 neurologists and 50 geriatricians demonstrated that 90% physicians would routinely use the results of DISCERN.
- While there are tests for identifying the presence of amyloid, only DISCERN has demonstrated >95% sensitivity and specificity to identify AD itself in people living with dementia or mixed dementia.